S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
How major US stock indexes fared Friday, 2/23/2024
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
How major US stock indexes fared Friday, 2/23/2024
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
How major US stock indexes fared Friday, 2/23/2024
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
How major US stock indexes fared Friday, 2/23/2024
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 2/19 - 2/23

Merus (MRUS) Stock Price, News & Analysis

$47.45
+0.18 (+0.38%)
(As of 02/23/2024 ET)
Today's Range
$46.26
$47.99
50-Day Range
$24.95
$47.45
52-Week Range
$17.15
$47.99
Volume
506,522 shs
Average Volume
535,680 shs
Market Capitalization
$2.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60

Merus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6.0% Downside
$44.60 Price Target
Short Interest
Bearish
8.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.07mentions of Merus in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$576,852 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.62) to ($3.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.42 out of 5 stars

Medical Sector

878th out of 939 stocks

Pharmaceutical Preparations Industry

409th out of 435 stocks


MRUS stock logo

About Merus Stock (NASDAQ:MRUS)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Stock Price History

MRUS Stock News Headlines

MRUS Mar 2024 40.000 call
MRUS Sep 2024 55.000 call
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Merus to Participate in Upcoming Investor Conferences
Merus Stock: Rally Seems Overdone
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
Merus: (Maybe) Building A Better Bispecific
Merus: Buy Rating Justified by Clinical Progress and Market Potential
Merus NV MRUS
See More Headlines
Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
2/24/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRUS
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.60
High Stock Price Target
$49.00
Low Stock Price Target
$35.00
Potential Upside/Downside
-6.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-131,190,000.00
Net Margins
-387.00%
Pretax Margin
-381.43%

Debt

Sales & Book Value

Annual Sales
$41.59 million
Book Value
$5.34 per share

Miscellaneous

Free Float
55,250,000
Market Cap
$2.74 billion
Optionable
Optionable
Beta
1.04
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Sven Ante Lundberg M.D. (Age 61)
    CEO, President & Executive Director
    Comp: $953.06k
  • Mr. Gregory D. Perry (Age 64)
    CFO & Principal Financial Officer
    Comp: $63.76k
  • Mr. Peter B. Silverman J.D. (Age 46)
    EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
    Comp: $601.19k
  • Dr. Hui Liu Ph.D. (Age 57)
    Chief Business Officer, Executive VP & Head of Merus U.S.
    Comp: $597.7k
  • Dr. Andrew Joe M.D. (Age 58)
    Chief Medical Officer & Senior VP
    Comp: $692.74k
  • Dr. Hennie Hoogenboom
    Co-Founder and Scientific Advisor
  • Harry Shuman
    Chief Accounting Officer
  • Mr. Cornelis Adriaan de Kruif Ph.D. (Age 59)
    CTO & Executive VP
    Comp: $349k
  • Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
    Chief Scientific Officer & Senior VP
  • Ms. Jillian Connell
    VP of Investor Relations & Corporate Communications














MRUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Merus stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings
or view top-rated stocks.

What is Merus' stock price target for 2024?

11 Wall Street research analysts have issued 1 year target prices for Merus' stock. Their MRUS share price targets range from $35.00 to $49.00. On average, they anticipate the company's stock price to reach $44.60 in the next year. This suggests that the stock has a possible downside of 6.0%.
View analysts price targets for MRUS
or view top-rated stocks among Wall Street analysts.

How have MRUS shares performed in 2024?

Merus' stock was trading at $27.50 at the beginning of the year. Since then, MRUS shares have increased by 72.5% and is now trading at $47.45.
View the best growth stocks for 2024 here
.

When is Merus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our MRUS earnings forecast
.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) released its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.14. The biotechnology company had revenue of $13.67 million for the quarter, compared to analyst estimates of $10.53 million. Merus had a negative trailing twelve-month return on equity of 63.39% and a negative net margin of 387.00%.

What ETFs hold Merus' stock?

ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Merus own?
When did Merus IPO?

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' stock is owned by a number of institutional and retail investors. Top institutional investors include Commodore Capital LP (8.22%), Federated Hermes Inc. (6.30%), RTW Investments LP (4.11%), Franklin Resources Inc. (3.26%), Balyasny Asset Management L.P. (2.14%) and Avoro Capital Advisors LLC (1.54%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg.
View institutional ownership trends
.

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRUS) was last updated on 2/24/2024 by MarketBeat.com Staff